Context: Human placenta exhibits a specific microRNA (miRNA) expression pattern. Some of these miRNAs are dysregulated in pregnancy disorders such as preeclampsia and intrauterine growth restriction and are potential biomarkers for these pathologies.
F
etal development represents a critical period during which perturbations to the intrauterine environment as a result of various factors in the extrauterine environment can have major effects, not only on the proper growth and development of the fetus, but also on disease risk later in life (1) . One of the most common perturbations during pregnancy is obesity.
Pregnancy in obese mothers generates an adverse intrauterine environment that causes a proinflammatory milieu and a number of metabolic derangements. Obesity influences the outcome of pregnancy per se, because it is associated with hypertensive disorders, gestational diabetes, and thromboembolic events (2) . In addition, maternal obesity affects the fetus and newborn, resulting in large-forgestational-age and intrauterine growth-restricted infants, and leads to subsequent complications in later life, including obesity, cardiovascular disease, and diabetes as a result of fetal programming (3) .
Development of the human placenta is critical for embryonic development and successful pregnancy. The placenta serves the bidirectional connection between the mother and the fetus and facilitates the exchange of nutrients, respiratory gases, and waste products during pregnancy. It is also an endocrine organ that produces hormones and growth factors that are crucial for embryonic development (4) . The mechanisms by which in utero exposures may alter the regulatory mechanisms of the placenta continue to be studied. One mode of alteration may be through the aberrant expression of microRNAs (miRNAs). Alterations in placental miRNA expression have been associated with adverse pregnancy outcomes, including preeclampsia and intrauterine growth restriction (5) (6) (7) (8) (9) (10) (11) (12) . No studies have been performed in pregnancies with maternal obesity.
We aimed to study the placental miRNA profile in pregnant women with prepregnancy overweight/obesity (preOB) and gestational obesity (gestOB), and explore the associations between placental miRNAs dysregulated in maternal obesity and prenatal and postnatal growth.
Material and Methods

Subjects and study approval
The study population consisted of 70 pregnant white women with uncomplicated pregnancies (other than pregestational obesity or gestOB) delivering appropriate-for-gestational-age term infants (gestational age between 37 and 42 weeks). Subjects were consecutively recruited among those seen within a setting of prenatal primary care in Girona (Spain). Women with multiple pregnancies, gestational diabetes, preeclampsia, fetal malformations, or asphyxia or drug use were excluded. Women were grouped according to their pregestational body mass index (pregestBMI) and their pregnancy weight gain into: (1) control (pregestBMI, .18.5 and ,24.9; pregnancy weight gain, .11.5 kg and ,16 kg); (2) preOB (pregestBMI, .25; pregnancy weight gain, .7 kg and ,11.5 kg); and (3) gestOB (pregestBMI, .18.5 and ,24.9; pregnancy weight gain, .16 kg), as previously described by the Institute of Medicine (13) . The protocol was approved by the Institutional Review Board of Dr. Josep Trueta Hospital. Informed written consent was obtained from the women.
Clinical assessments
A close prenatal follow-up, consisting of clinical exams according to standardized protocols, ultrasonograms, and laboratory tests (urine and blood), was performed in all subjects. Information on maternal pregnancy characteristics was abstracted from standardized medical records. PregestBMI was calculated as weight divided by height squared (kg/m 2 ). Newborns were weighed and measured after delivery using a calibrated scale for weight and a measuring board for length. Infants were followed for weight and length measurements at 1, 4 and 12 months of age.
The placentas were collected immediately after childbirth in the delivery room or operating room to ensure sterility and speed. Placentas were weighed and three, 1 cm 3 cuboidal sections were collected from the inner surface of the placenta (maternal side) after removing the decidua layer, and thus contained placental villous tissue. The samples were preserved in RNA later and stored at -80°C until miRNA extraction. The personnel handling the placenta and samples wore facial masks and sterile gloves and used a sterile scalpel and instruments.
Analytical methods
Blood tests were performed under fasting conditions in all women between 24 and 32 weeks of gestation. Serum glucose was analyzed by the hexokinase method. Serum immunoreactive insulin was measured by immunochemiluminescence (Immulite 2000; Diagnostic Products, Los Angeles, CA). Fasting insulin sensitivity was estimated using the following formula: homeostasis model for assessment of insulin resistance (HOMA-IR) = (fasting insulin in mU/L) 3 (fasting glucose in mM) / 22.5. Glycosylated hemoglobin was measured by high-performance liquid chromatography (Bio-Rad, Muenchen, Germany) and a Jokoh HS-10 autoanalyzer (Bio-Rad). Serum C-peptide was measured by immunochemiluminescence (IMMULITE 2000; Diagnostic Products). Total serum triacylglycerol was measured by monitoring the reaction of glycerol-phosphate oxidase and peroxidase. High-density lipoprotein (HDL) cholesterol was quantified by the homogeneous method of selective detergent with accelerator.
Analysis of placental miRNAs
Placental miRNA extraction and reverse transcription Total RNA (including miRNAs) was isolated from placental samples with the mRNAeasy mini Kit (Qiagen, Madrid, Spain). The quantity of isolated RNA was determined with a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE), and the integrity of each RNA sample was checked with an Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA). RNA was reverse transcribed using TaqMan MicroRNA Reverse Transcription Kit and Megaplex RT primers (human pool sets A and B) (Applied Biosystems, Foster City, CA).
Placental miRNA profiling
We studied the placental miRNA profiles in 18 pregnant women (six preOB, six gestOB, and six control) who were randomly selected from the studied subjects. The sampling method was designed to ensure that the sample would be representative of the study subjects, taking into account maternal BMI, age, and sex of the newborn. A TaqMan Array Human MicroRNA Card Set (version 3.0; Applied Biosystems) that enables accurate quantification of 723 human miRNAs was used. Real-time polymerase chain reaction (RT-PCR) was carried out on an Applied BioSystems 7900HT thermocycler. Data were analyzed with Sequence Detection Systems Relative Quantification Software version 2.2.2 (Applied Biosystems) and the R package SL qpcrNorm (Bioconductor; https://www.bioconductor.org). The placental miRNA profile was compared with the specific secondtrimester plasma profile that we previously described in the same cohort using the same methodology (14) .
Analysis of individual miRNAs
Individual TaqMan MicroRNA Assays (Applied Biosystems) were used to study the presence of placental miRNA candidates in the studied subjects: 70 pregnant women (20 with preOB, 25 with gestOB, and 25 women with normal pregnancies), including the subjects previously studied to determine the miRNA profile. Gene expression was assessed by RT-PCR using the LightCycler 480 Real-Time PCR System (Roche Diagnostics, Indianapolis, IN), as previously described (14) . We performed DCt normalization as implemented in the HTqPCR package (Bioconductor; https://www.bioconductor.org), using the three most stable (rank-invariant) miRNAs in placenta (pool A: miR-523, miR-532, miR-425-5p; pool B: miR-30e-3p, miR-519b-3p, miR-520d-3p) as reference. Relative miRNA levels were calculated according to the 2 -DCt method.
miRNA target prediction
Pathways targeted by our candidate miRNAs were predicted using the Web-based tool, miRSystem (15) . miRSystem integrates several databases (Kegg, Biocarta, Pathway Interaction Database, Reactome, and GO molecular function; http:// mirsystem.cgm.ntu.edu.tw/) to enable prediction of gene targets and targeted pathways.
Statistical analysis
Results are expressed as mean 6 standard error of the mean. Nonparametric variables were logarithmically transformed to improve symmetry. Unpaired t test or one-way analysis of variance were used to study differences in continuous variables among groups. The relation between variables was analyzed by simple correlation followed by multiple regression analysis in a stepwise manner. Significance level was set at P , 0.05. Data analyses were performed with SPSS (v. 22.0; SPSS, Chicago, IL) and R (http:// www.r-project.org/) statistical software. The SL qPCRNorm Package (Bioconductor; https://www.bioconductor.org) was also used for the analysis and normalization of miRNA data (16) .
Results
Placental miRNA profile
From the 723 human miRNAs screened by TaqMan Low Density Arrays (TLDAs; specifically, the TaqMan Array Human MicroRNA), 486 miRNAs were expressed in the human placentas used in this study, which were categorized into three study groups, namely, normal placentas (control), placentas from women with gestOB, and placentas from women with preOB.
We first focused on the abundance of the miRNAs. miR-517-3p, miR-1274b, miR-1243, miR-24-3p, miR-517c-3p, miR-888-5p, miR-545-5p, miR-302a-3p, miR-126-3p, and miR-223-3p were the 10 most abundant miRNAs in control placentas. All of these miRNAs were also highly expressed in preOB and gestOB placentas. miR-517-3p, miR-1274b, miR-1243, miR-24-3p, and miR-517c-3p were the most abundantly expressed in both groups. All of these miRNAs were present in second-trimester plasma from all subjects, except for miR-888, which was only present in the control group, and miR-1274b and miR-545-5p, which were not present in any of the studied groups. miR-1243 and miR-223-3p were highly expressed in the second-trimester plasma of all studied groups (Supplemental Table 1 ).
With respect to the chromosomal distribution, the miRNAs found to be expressed in these placentas were located on all chromosomes except the Y chromosome. The predominant miRNAs were derived from chromosome 19 (about 15%), followed by chromosome 14 (about 11%) and chromosome X (about 11%).
We next directed our attention to the miRNAs expressed in the different placental groups ( Fig. 1 ; Supplemental Table 2 ). Four hundred and four miRNAs were detected in all studied groups. Fourteen miRNAs were only expressed in control placentas; 15 miRNAs were only expressed in placentas from gestOB subjects, and 13 miRNAs were only expressed in placentas from preOB subjects. The majority of the miRNAs were placental-specific miRNAs and were not present in second-trimester plasma samples, except for miR144-3p, which was highly expressed in placentas from preOB subjects. 
Differential miRNAs in maternal obesity
Among the 404 miRNAs detected in all studied groups, we focused on 18 miRNAs which were up-or downregulated by at least twofold in placentas from preOB and gestOB women compared with control subjects (miR-100, miR-1269, miR-1271, miR-1285, miR-181, miR-185, miR-191, miR-214, miR-23, miR-27, miR-29, miR-296, miR-337, miR-339, miR-365, miR-483, miR-487, and miR-520h). These 18 miRNAs were chosen as candidates for miRNAs differentially regulated by maternal obesity and were validated by RT-PCR in a wider population consisting of 70 pregnant women (20 preOB, 25 gestOB, and 25 control) ( Table 1) .
Eight of the 18 miRNAs were confirmed to be differentially expressed between placentas from women with normal pregnancies and obese women. Among them, miR-100, miR-185, and miR-487 were decreased in gestOB compared with control, and miR-1269, miR-1285, miR-181, miR-214, and miR-296 were decreased in both preOB and gestOB compared with control (all P , 0.03) ( Table 1 ; Fig. 2 ).
Association with maternal metabolic parameters
Several of the placental miRNAs dysregulated in maternal obesity were associated with maternal metabolic parameters including decreased BMI, HOMA-IR, and C-peptide and increased high-molecular-weight (HMW) adiponectin and HDL cholesterol ( Table 2 ). Significant associations, after correcting for multiple comparisons, included the association of miR-1269 with HMW adiponectin, and miR-296 with HMW adiponectin and HOMA-IR (all P # 0.006; Table 2 ). These associations remained significant in multiple regression analysis adjusting for confounding variables including gestational age, maternal age, pregestational BMI, maternal weight gain, and sex of the newborn (Table 3) .
Association with growth parameters
Some of the placental miRNAs dysregulated in maternal obesity were also significantly associated with growth parameters at birth and thereafter during the 12 months of follow-up, including negative associations with placental weight, birth weight standard deviation score (SDS), and birth length SDS, and positive associations with weight gain SDS at 1, 4, and 12 months of age (Table 2 ; Supplemental Figs. 1-2). Significant associations after correcting for multiple comparisons include the association of miR-100, miR-1285, and miR-487 with birth weight SDS and miR-296 with birth weight SDS and increased weight gain SDS at 4 and 12 months of age (all P # 0.006; Table 2 ).
In multiple regression analysis, miR-487 was an independent predictor of placental weight and explained 13% of its variance. miR-100, miR-1285, miR-296, and miR-487 were independent predictors of birth weight and explained nearly 30% of its variance. miR-100, miR-1285, and miR-487 were independent predictors of birth length and explained nearly 30% of its variance. miR-100, miR-1285, and miR-487 were independent predictors of weight gain in the first month of life and explained nearly 15% of its variance. miR-100, miR-296, and miR-487 were independent predictors of weight gain at 4 and 12 months of age and explained nearly 20% of its variance (Table 3) .
Predicted miRNA pathways
Given the association of miR-100, miR-1285, miR-296, and miR-487 with growth parameters, we conducted an in silico analysis to ascertain their associated pathways and whether common mRNA targets were shared to a significant extent by these miRNAs. Predictors using miRSystem indicated that, excluding pathways in cancer, these four miRNAs shared targets related to WNT, MAPK, mTOR, and insulin/IGF-1 signaling pathways (Table 4) .
Placenta-specific miRNAs in maternal plasma
Finally, we assessed the circulating levels of our placental, obesity-associated miRNAs in second-trimester, cellfree maternal plasma of the studied subjects by quantitative PCR. miR-100, miR-1269a, miR-1271, miR-1285, miR181a, and miR-27a were not expressed in plasma samples. miR-23b and miR-483 were only expressed in controls.
Among the miRNAs expressed in plasma, miR-296 was decreased in preOB and gestOB compared with control subjects (P = 0.001 and P = 0.04), and miR-520h was increased in both groups compared with control subjects (P = 0.01 and P = 0.004).
Circulating miR-296 in second-trimester plasma was associated with placental miR-296 (r = 0.310; P = 0.008), placental weight (r = 20.258; P = 0.03), birth weight SDS (r = 20.297; P = 0.01), birth length SDS (r = 20.315; P = 0.008), and weight gain SDS at 12 months of age (r = 0.325; P = 0.01). These associations with placental weight (b = 20.260; P = 0.03), birth weight (b = 20.252; P = 0.03), birth length (b = 20.326; P = 0.006), and weight gain at 12 months (b = 0.206; P = 0.02) were maintained in multivariate analysis after adjusting for maternal and newborn parameters.
Discussion
We have described the specific placental miRNA profile in pregestational and gestOB and have shown how a number of miRNAs dysregulated in maternal obesity (miR-100, miR-1285, miR-296, and miR487) were predictors of decreased birth weight and increased weight gain at 1, 4, and/ or 12 months of life, independently of maternal obesity.
miRNA expression profiling of the human placenta by TLDAs
To date, more than 500 miRNAs have been reported to be expressed by the human placenta. We detected 486 ).
Abbreviations: HDL-c, HDL cholesterol; TG, triglycerides. a P # 0.005 vs control subjects.
b P # 0.005 vs gestOB subjects.
c P # 0.05 vs gestOB subjects. miRNAs expressed in the human placentas of control, preOB, and gestOB. The 10 most expressed miRNAs in our study groups were also detected in second-trimester plasma (14) . Among them, miR-24, miR-126, miR-223, and miR-517 have been previously described to be expressed in placenta and plasma from pregnant women and were reported to be dysregulated in preeclampsia (6, 7, 12) . A remarkable observation regarding human placental miRNAs is the abundance of a family of miRNAs originating from two genomic clusters that are located on chromosome 19 (C19MC) and chromosome 14 (C14MC) https://academic.oup.com/jcem (17) . In agreement with these observations, we found that 15% and 11% of the miRNAs expressed in placenta are located in chromosome 19 and 14, respectively. Some studies showed that C19MC miRNAs changed in obstetrical diseases, such as preeclampsia and fetal growth restriction (18) . However, among the placental obesityassociated miRNAs that were observed in our study, only miR-520h is located in the C19MC cluster. miR-520h is increased in second-trimester plasma of preOB and gestOB women compared with controls. No significant differences were observed in placental tissue. The comparison of the placental miRNA profile from the studied groups showed that 13 miRNAs were specific to placentas from women with preOB, 15 miRNAs were specific to placentas from women with gestOB, and 14 miRNAs were specific to placentas from control women. The majority of these miRNAs were not present in plasma samples, except for miR-144-3p, which was highly expressed in placentas from preOB. miR-144 was described to be a miRNA with diagnostic potential for pregnancy-associated complications and was detected by high-throughput sequencing and a quantitative PCRbased array in preeclamptic placentas (7) . miR-144 has been related to glucose metabolism by its regulation of GLUT1 (19) and IRS1 (20) .
Differential miRNAs in maternal obesity
We next focused on the miRNAs which were up-or downregulated by at least twofold in placentas from preOB and gestOB women compared with control subjects, and studied their association with maternal metabolic parameters and prenatal and postnatal growth.
Among the 18 miRNAs chosen as candidates for miRNAs that were differentially regulated by maternal obesity, eight miRNAs (miR-100, miR-1269, miR-1285, miR-181, miR-185, miR-214, miR-296, and miR487) were confirmed to be downregulated in placentas from obese women. miR-100, miR-181, miR-185, miR-214, and miR-296 were previously described to be related to obesity and/or type 2 diabetes (21) (22) (23) (24) (25) (26) (27) . In agreement with these results, we showed that placental levels of these miRNAs were associated with maternal metabolic parameters, including delivery BMI, HMW adiponectin, HDL cholesterol, HOMA-IR, and C-peptide.
Association with growth parameters
Among the eight placental miRNAs that were differentially expressed in maternal obesity, four miRNAs (miR-100, miR-1285, miR-296, and miR-487) were associated with lower birth weight and increased weight gain at 1, 4, and/or 12 months of age. miR-100 is downregulated in placental tissue from fetuses with intrauterine growth restriction (8) and in patients with obesity and diabetes and modulates IGFR and mTOR signaling in adipose tissue in vitro (21). miR-1285 was not previously related to pregnancy disorders but has been associated with several cancers because of its regulation of its targets Jun and p53 (28, 29) . In pigs, miR-1285 regulates AMPK and mTOR in Sertoli cells (30) and is upregulated in the liver of piglets exposed to methyldonor nutrients during gestation (31) . miR-296 was found to be dysregulated in placentas of patients with preeclampsia and preterm labor (9, 10) . miR-296 was increased in maternal plasma of pregnant women with severe preeclampsia (9, 11) and downregulated by high glucose treatment (32) . Moreover, in pancreatic a cells, it controls the expression of IGF1Rb, its downstream targets phospho-IRS-1 and phospho-ERK, and TNFa (33) . In particular, miR-200 family members play a crucial role in oxidative stress-dependent endothelial dysfunction, as well as in vascular complications of diabetes and obesity (34) . miR-487 was previously described as a pregnancy-associated miRNA that was produced predominantly in the placenta and detected only in first-trimester plasma samples (6) . In agreement with these observations, our in silico analyses using the miRSystem database (15) showed that these miRNAs were related to insulin/IGF-1, mTOR, MAPK, and WNT signaling pathways. Placental insulin/IGF-1 and mTOR signaling pathways stimulate placental amino acid transport and contribute to increased fetal growth (35) . MAPK and PI3K-AKT signaling pathways were demonstrated to control human trophoblast invasion and so are also related to fetal growth (36) . A role has been described for WNT signaling in human fetal development (37) . Taken together, these data give support to a potential role of miR-100, miR-1285, miR-296, and miR-487 in modulating prenatal and postnatal growth.
Placenta-specific miRNAs in maternal plasma Specific placental miRNAs can be released into the circulation and reflect the physiological state of pregnancy. Their concentration and their profiles in the plasma make them possible candidates as biomarkers for the detection of pregnancy complications that are linked to placental pathologies (38) .
We have recently described the pattern of the circulating miRNA profile from the second trimester of pregnancy in the same cohort and using the same methodology (14) . We identified 13 circulating miRNAs that were differentially expressed in maternal obesity. These miRNAs were present in placental samples, but significant differences among obesity groups and controls were not observed with the placental TLDAs study, and therefore, were not analyzed in the present work. Other tissues rather than placenta could be the source of these miRNAs that are dysregulated in the plasma of obese pregnant women.
On the other hand, we have compared the placental miRNA profile obtained in this work with the secondtrimester miRNA profile obtained in our previous work with TLDAs (14) , and we have observed that several of the studied placental miRNAs were also expressed in plasma. The validation of these placental miRNAs in the plasma samples of all study subjects by quantitative PCR showed that circulating miR-296 was also decreased in plasma from preOB and gestOB subjects compared with control subjects, and its expression was associated with its placental expression. Moreover, circulating miR-296 was associated with placental weight, birth weight SDS, birth length SDS, and weight gain SDS at 12 months of age. These results reinforce the suggestion of a possible role of placental miR-296 in regulating prenatal and postnatal growth.
It is noteworthy that both circulating and placental miR-296 relate to prenatal and postnatal weight gain, but in opposing ways. We suggest that miR-296 may be a midgestational circulating marker for the offspring sequence of prenatal restraint and postnatal catch-up, which in turn is associated with subsequent insulin resistance and its correlates. A high miR-296 value may be predictive of such a sequence, and may contribute to guide obstetricians as to whether to anticipate a premature delivery to prevent this sequence and its long-term correlates.
The other placental miRNAs related to prenatal and postnatal growth (miR-100, miR-1285, and miR-487) were not expressed in second-trimester plasma samples. However, the Internet-based database ExoCarta (http:// www.exocarta.org/) shows that all of these miRNAs had been identified in exosomes derived from several human cells, suggesting that these miRNAs could be found in the human circulation. Although we have not detected them in second-trimester plasma samples, they could be released later into maternal circulation and affect fetal growth during the third trimester. In relation to this, Zhao et al. (7) described some miRNAs that were detectable in maternal plasma during pregnancy but were undetectable in third-trimester, postdelivery plasma, and vice versa. The discrepancy between placental and plasma miRNAs has also been found for specific miRNAs dysregulated in other pregnancy disorders (5, 39, 40) . The nonsignificant correlation between placental and maternal plasma miRNA is nevertheless intriguing. This may reflect related processes in which placental dysfunction attenuates miRNA biogenesis and alters exosomedependent or exosome-independent release of miRNAs into the plasma. Further investigation of this discrepancy will be important to better understand how placentaspecific miRNAs are released into maternal circulation. However, the effect of the miRNAs that are not released into the maternal plasma during pregnancy could be exerted via a paracrine regulation between trophoblasts and fetal cells, through the fetal circulation, or by an autocrine regulation of the trophoblasts themselves, through the regulation of several proteins released by the trophoblast and involved in the regulatory mechanism of fetal growth.
In summary, our data provide evidence that the placenta responds to the maternal obesogenic environment by expressing a specific placental miRNA profile. We identified eight placenta obesity-associated miRNAs, four of which (miR-100, miR-1285, miR-296, and miR-487) were related to prenatal and postnatal growth parameters. Among them, miR-296 was present in second-trimester plasma samples and was associated with placental expression as well as with prenatal and postnatal growth. Our results led to the identification of altered regulatory placental miRNAs that may participate in the mediation of growth-promoting effects of maternal obesity on the offspring and could be used as early markers of prenatal and postnatal growth.
